Soichiro Tajima

Dr. Soichiro Tajima


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Life Sciences
Verified
Journal Article
Closed access
TSTomohiro Shigematsu
Tomohiro Shigematsu
STSoichiro Tajima
Soichiro Tajima
RFRao Fu
Rao Fu
MZMengyu Zhang
Mengyu Zhang
YIYuuka Itoyama
Yuuka Itoyama
IIIchiro Ieiri
Ichiro Ieiri

1 May 2021 in Toxicology Letters
Verified
Journal Article
Closed access
RFRao Fu
Rao Fu
STSoichiro Tajima
Soichiro Tajima
TSTomohiro Shigematsu
Tomohiro Shigematsu
MZMengyu Zhang
Mengyu Zhang
ATAkihiro Tsuchimoto
Akihiro Tsuchimoto
Satohiro MasudaSatohiro Masuda
Satohiro Masuda

Verified
Journal Article
Open access
PDF file
STSoichiro Tajima
Soichiro Tajima
RFRao Fu
Rao Fu
TSTomohiro Shigematsu
Tomohiro Shigematsu
HNHiroshi Noguchi
Hiroshi Noguchi
KKKeizo Kaku
Keizo Kaku
Satohiro MasudaSatohiro Masuda
Satohiro Masuda
Kidney transplantation is the treatment of choice for patients with advanced chronic kidney disease (CKD) and end stage renal disease (ESRD). However, acute rejection (AR) is a common complication in kidney transplantation and is associated with reduced graft survival. Current diagnosis of AR relies mainly on clinical monitoring including serum creatinine, proteinuria, and confirmation by histopathologic assessment in the biopsy specimen of graft kidney. Although an early protocol biopsy is indispensable for depicting the severity of pathologic lesions in subclinical acute rejection (subAR), it is not acceptable in some cases and cannot be performed because of its invasive nature. Therefore, we examined the detection of noninvasive biomarkers that are closely related to the pathology of subAR in protocol biopsies three months after kidney transplantation. In this study, the urinary level of microtubule-associated protein 1 light chain 3 (LC3), monocyte chemotactic protein-1 (MCP-1), liver-type fatty acid-binding protein (L-FABP), neutrophil gelatinase-associated lipocalin (NGAL), and human epididymis secretory protein 4 (HE4) were measured three months after kidney transplantation. Urine samples of 80 patients undergoing kidney transplantation between August 2014 to September 2016, were prospectively collected after three months. SubAR was observed in 11 patients (13.8%) in protocol biopsy. The urinary levels of LC3, MCP-1, NGAL, and HE4 were significantly higher in patients with subAR than in those without, while those of L-FABP did not differ between the two groups. Multivariate regression models, receiver-operating characteristics (ROC), and areas under ROC curves (AUC) were used to identify predicted values of subAR. Urinary HE4 levels were able to better identify subAR (AUC = 0.808) than the other four urinary biomarkers. In conclusion, urinary HE4 is increased in kidney transplant recipients of subAR three months after kidney transplantation, suggesting that HE4 has the potential to be used as a novel clinical biomarker for predicting subAR.

Verified
Journal Article
Open access
PDF file
MZMengyu Zhang
Mengyu Zhang
STSoichiro Tajima
Soichiro Tajima
TSTomohiro Shigematsu
Tomohiro Shigematsu
RFRao Fu
Rao Fu
HNHiroshi Noguchi
Hiroshi Noguchi
Satohiro MasudaSatohiro Masuda
Satohiro Masuda
CYP3A5 gene polymorphism in recipients plays an important role in tacrolimus blood pharmacokinetics after renal transplantation. Even though CYP3A5 protein is expressed in renal tubular cells, little is known about the influence on the tacrolimus intrarenal exposure and hence graft outcome. The aim of our study was to investigate how the tacrolimus intrarenal concentration (Ctissue) could be predicted based on donor CYP3A5 gene polymorphism in renal transplant recipients. A total of 52 Japanese renal transplant patients receiving tacrolimus were enrolled in this study. Seventy-four renal biopsy specimens were obtained at 3 months and 1 year after transplantation to determine the donor CYP3A5 polymorphism and measure the Ctissue by liquid chromatography-tandem mass spectrometry (LC-MS-MS). The tacrolimus Ctissue ranged from 52 to 399 pg/mg tissue (n = 74) and was weak but significantly correlated with tacrolimus trough concentration (C0) at 3 months after transplantation (Spearman, r = 0.3560, p = 0.0096). No significant relationship was observed between the donor CYP3A5 gene polymorphism and Ctissue or Ctissue/C0. These data showed that the tacrolimus systemic level has an impact on tacrolimus renal accumulation after renal transplantation. However, donor CYP3A5 gene polymorphism alone cannot be used to predict tacrolimus intrarenal exposure. This study may be valuable for exploring tacrolimus renal metabolism and toxicology mechanism in renal transplant recipients.

Verified
Journal Article
Open access
PDF file
MFMio Fukuda
Mio Fukuda
KSKimitaka Suetsugu
Kimitaka Suetsugu
STSoichiro Tajima
Soichiro Tajima
YKYurie Katsube
Yurie Katsube
HWHiroyuki Watanabe
Hiroyuki Watanabe
Satohiro MasudaSatohiro Masuda
Satohiro Masuda
Tacrolimus is widely used as an immunosuppressant in liver transplantation, and tacrolimus-induced acute kidney injury (AKI) is a serious complication. The urinary neutrophil gelatinase-associated lipocalin (NGAL) level has been linked to tacrolimus-induced AKI in patients starting tacrolimus treatment the morning after liver transplantation. Here we tested this association using a different immunosuppression protocol: Mycophenolate mofetil administration beginning on Postoperative Day 1 and tacrolimus administration beginning on Postoperative Day 2 or 3. Urine samples were collected from 26 living donor liver transplant recipients before (Postoperative Day 1) and after (Postoperative Day 7 or 14) tacrolimus administration. NGAL levels were measured via enzyme-linked immunosorbent assays, as were those of three additional urinary biomarkers for kidney diseases: Monocyte chemotactic protein-1 (MCP-1), liver-type fatty acid-binding protein (L-FABP), and human epididymis secretory protein 4 (HE4). HE4 levels after tacrolimus administration were significantly higher in patients who developed AKI (n = 6) than in those who did not (n = 20), whereas NGAL, MCP-1, and L-FABP levels did not differ significantly before or after tacrolimus administration. These findings indicate that NGAL may not be a universal biomarker of AKI in tacrolimus-treated liver transplant recipients. To reduce the likelihood of tacrolimus-induced AKI, our immunosuppression protocol is recommended.

28 June 2021 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
MZMengyu Msc Zhang
Mengyu Msc Zhang
STSoichiro Tajima
Soichiro Tajima
TSTomohiro Bsc Shigematsu
Tomohiro Bsc Shigematsu
HNHiroshi Noguchi
Hiroshi Noguchi
KKKeizo Kaku
Keizo Kaku
IIIchiro Ieiri
Ichiro Ieiri
Background: Therapeutic drug monitoring is necessary for immunosuppressive therapy with tacrolimus and everolimus after kidney transplantation. Several studies have suggested that the concentrations of immunosuppressive agents in allografts may better reflect clinical outcomes than whole blood concentrations. This study aimed to develop a method for the simultaneous quantification of tacrolimus and everolimus concentrations in clinical biopsy samples and investigate their correlation with histopathological findings in kidney transplant recipients. Methods: Fourteen biopsy samples were obtained from kidney transplant recipients at 3 months after transplantation. Kidney allograft concentrations (Ctissue) of tacrolimus and everolimus were measured by liquid chromatography–tandem mass spectrometry, and the corresponding whole blood trough concentrations (C0) were obtained from clinical records. Results: The developed method was validated over a concentration range of 0.02–2.0 ng/mL for tacrolimus and 0.04–4.0 ng/mL for everolimus in kidney tissue homogenate. The Ctissue of tacrolimus and everolimus in kidney biopsies ranged from 21.0 to 86.7 pg/mg tissue and 33.5–105.0 pg/mg tissue, respectively. Dose-adjusted Ctissue of tacrolimus and everolimus was significantly correlated with the dose-adjusted C0 (P < 0.0001 and P = 0.0479, respectively). No significant association was observed between the Ctissue of tacrolimus and everolimus and the histopathologic outcomes at 3 months after transplantation. Conclusions: This method could support further investigation of the clinical relevance of tacrolimus and everolimus allograft concentrations after kidney transplantation.